{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:37:09Z","timestamp":1770680229691,"version":"3.49.0"},"reference-count":17,"publisher":"BMJ","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart"],"published-print":{"date-parts":[[1984,3,1]]},"DOI":"10.1136\/hrt.51.3.316","type":"journal-article","created":{"date-parts":[[2007,9,18]],"date-time":"2007-09-18T21:46:00Z","timestamp":1190151960000},"page":"316-320","source":"Crossref","is-referenced-by-count":58,"title":["The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone."],"prefix":"10.1136","volume":"51","author":[{"given":"N M","family":"Debbas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"du Cailar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R S","family":"Bexton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J G","family":"Demaille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A J","family":"Camm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Puech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","reference":[{"key":"ref_1","first-page":"657","article-title":"The effect of amiodarone, a new anti-aninal drug, on cardiac muscle","volume":"39","author":"Singh, B.N.; Vaughan Williams, E.M.","year":"1970","unstructured":"Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-aninal drug, on cardiac muscle. Br 7 Phrmacol 1970; 39: 657-67."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1476-5381.1970.tb09893.x","article-title":"A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ1999 and AM3474","volume":"39","author":"Singh, B.N.; Vaughan Williams, E.M.","year":"1970","unstructured":"Singh BN, Vaughan Williams EM. A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ1999 and AM3474. BrJ Pharmacol 1970; 39: 675-87.","journal-title":"BrJ Pharmacol"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0163-7258(82)90020-1","article-title":"Drugs with a class III antiarrhythmic action","volume":"17","author":"Bexton, R.S.; Camm, A.J.","year":"1982","unstructured":"Bexton RS, Camm AJ. Drugs with a class III antiarrhythmic action. Pharmacol Ther 1982; 17: 315-55.","journal-title":"Pharmacol Ther"},{"key":"ref_4","first-page":"191","article-title":"Intravenous amiodarone: an effective antiarrhythmic agent","volume":"47","author":"Curry, P.V.L.; Holt, P.; Way, B.; Awar, S.; Holt, D.","year":"1982","unstructured":"Curry PVL, Holt P, Way B, Awar S, Holt D. Intravenous amiodarone: an effective antiarrhythmic agent [Abstract]. Br HeartJ 1982; 47: 191.","journal-title":"Br HeartJ"},{"key":"ref_5","first-page":"297","article-title":"excluded from the analysis. There were highly Campbell RWF. Amiodarone tissue distribution: relasignificant relations between the increase in this measurement and amiodarone dosage and between plasma and myocardial concentrations. The higher the dosage, the longer the QTc intervals. A threshold dosage of 0 96 mg\/kg\/day was necessary to produce a measurable increase in the QTc interval. It has been previously suggested that the increase in the QTc interval is directly related to the efficacy of the drug,8 tion to adverse effects","volume":"49","author":"Adams, P.C.; Nicholson, M.R.; Storey, G.C.A.; Holt, D.W.","year":"1983","unstructured":"Adams PC, Nicholson MR, Storey GCA, Holt DW, excluded from the analysis. There were highly Campbell RWF. Amiodarone tissue distribution: relasignificant relations between the increase in this measurement and amiodarone dosage and between plasma and myocardial concentrations. The higher the dosage, the longer the QTc intervals. A threshold dosage of 0 96 mg\/kg\/day was necessary to produce a measurable increase in the QTc interval. It has been previously suggested that the increase in the QTc interval is directly related to the efficacy of the drug,8 tion to adverse effects [Abstract]. Br Heart7 1983; 49: 297."},{"issue":"177","key":"ref_6","first-page":"340","article-title":"Recherches dans la s6rie des benzofurannes XXXVII. Etude comparee du transit et du metabolisme de l'amiodarone chez diverses esptces animales et chez l'homme","volume":"1969","author":"Broekhuysen, J.; Laruel, R.; Sion, R.","unstructured":"Broekhuysen J, Laruel R, Sion R. Recherches dans la s6rie des benzofurannes XXXVII. Etude comparee du transit et du metabolisme de l'amiodarone chez diverses esptces animales et chez l'homme. Arch Int Pharmacodyn Ther 1969; 177: 340-59.","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"ref_7","first-page":"123","article-title":"Determination of cardiac and plasma drug levels during long term amiodarone therapy. EurJ7 Clin","volume":"13","author":"Debbas, N.; du Cailar, C.; Sassine, A.; Derancourt, J.; Demaille, J.; Puech, P.","year":"1983","unstructured":"Debbas N, du Cailar C, Sassine A, Derancourt J, Demaille J, Puech P. Determination of cardiac and plasma drug levels during long term amiodarone therapy. EurJ7 Clin Pharmcol 1983; 13: 123-7.","journal-title":"Pharmcol"},{"issue":"7","key":"ref_8","first-page":"353","article-title":"An analysis of the time-relations of the electrocardiograms","volume":"1920","author":"Bazett, H.C.","unstructured":"Bazett HC. An analysis of the time-relations of the electrocardiograms. Heart 1920; 7: 353-70.","journal-title":"Heart"},{"key":"ref_9","first-page":"840","article-title":"Amiodarone pharmacokinetics","volume":"106","author":"Holt, D.W.; Jackson, P.R.; Tucker, G.T.; Storey, G.C.A.","year":"1983","unstructured":"Holt DW, Jackson PR, Tucker GT, Storey GCA. Amiodarone pharmacokinetics. AmJ Cardiol 1983; 106: 840-7.","journal-title":"AmJ Cardiol"},{"key":"ref_10","first-page":"11","article-title":"Amiodarone myocardial concentrations correlate better than plasma concentrations with electrophysiologic effects","volume":"66","author":"Latini, R.; Connolly, S.; KernoffR, Kates; R.E.","year":"1982","unstructured":"Latini R, Connolly S, KernoffR, Kates RE. Amiodarone myocardial concentrations correlate better than plasma concentrations with electrophysiologic effects [Abstract]. Circulation 1982; 66: 11-223.","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/0002-8703(81)90140-X","article-title":"Clinical pharmacology and therapeutic applications of the antiarrhythmic agent, amiodarone","volume":"101","author":"Marcus, F.I.; Fontaine, G.H.; Frank, R.; Grosgogeat, Y.","year":"1981","unstructured":"Marcus FI, Fontaine GH, Frank R, Grosgogeat Y. Clinical pharmacology and therapeutic applications of the antiarrhythmic agent, amiodarone. Am Heart J 1981; 101: 480-93.","journal-title":"Am Heart J"},{"key":"ref_12","first-page":"297","article-title":"A peuliar cutaneous pigmentation from cordarone","volume-title":"Dermatologica","volume":"145","author":"Vos, A.K.; Van Ramshorst, A.G.S.; Grosfeld, J.C.M.; Goossens, J.P.","year":"1972","unstructured":"Vos AK, Van Ramshorst AGS, Grosfeld JCM, Goossens JP. A peuliar cutaneous pigmentation from cordarone. Dermatologica 1972; 145: 297-303."},{"key":"ref_13","first-page":"1205","article-title":"Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and elec- Debbas, du Cailar, Bexton, Demaille, Camm, Puech tron microscopic study","volume":"112","author":"Delage, C.; Lagace, R.; Huard, J.","year":"1975","unstructured":"Delage C, Lagace R, Huard J. Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and elec- Debbas, du Cailar, Bexton, Demaille, Camm, Puech tron microscopic study. Can Med Assoc J 1975; 112: 1205-8.","journal-title":"Can Med Assoc J"},{"key":"ref_14","first-page":"856","article-title":"Effects of amiodarone on thyroid function in patients with ischaemic heart disease","volume-title":"Br HeartJ7","volume":"37","author":"Pritchard, D.A.; Singh, B.N.; Hurley, P.J.","year":"1975","unstructured":"Pritchard DA, Singh BN, Hurley PJ. Effects of amiodarone on thyroid function in patients with ischaemic heart disease. Br HeartJ7 1975; 37: 856-60."},{"key":"ref_15","first-page":"53","article-title":"The effect of amiodarone on thyroid function","volume-title":"in cardiac arrhythmias","author":"Rees, L.; Ward, D.E.; El-Hamdi, A.; Camm, A.J.","year":"1979","unstructured":"Rees L, Ward DE, El-Hamdi A, Camm AJ. The effect of amiodarone on thyroid function. In: Simpson WT, Caldwell ADS, eds. Amiodarone in cardiac arrhythmias. London: Royal Society of Medicine and Academic Press, 1979: 53-6."},{"key":"ref_16","first-page":"192","article-title":"Amiodarone therapy: unwanted effects","volume":"47","author":"Harris, L.; McKenna, W.J.; Rowland, E.; Holt, D.W.; Krikler, D.M.","year":"1982","unstructured":"Harris L, McKenna WJ, Rowland E, Holt DW, Krikler DM. Amiodarone therapy: unwanted effects [Abstract]. BrHeartJ 1982; 47: 192.","journal-title":"BrHeartJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM198109033051002","article-title":"Amiodarone: clinical efficacy and electrophysiology during long term therapy for recurrent ventricular tachycardia or ventricular fibrillation","volume":"305","author":"Heger, J.J.; Prystowsky, E.N.; Jackman, W.M.","year":"1981","unstructured":"Heger JJ, Prystowsky EN, Jackman WM, et al. Amiodarone: clinical efficacy and electrophysiology during long term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med 1981; 305: 539-45.","journal-title":"N Engl J Med"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/hrt.51.3.316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:57:55Z","timestamp":1601081875000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/hrt.51.3.316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,3,1]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1984,3,1]]}},"URL":"https:\/\/doi.org\/10.1136\/hrt.51.3.316","relation":{},"ISSN":["1355-6037"],"issn-type":[{"value":"1355-6037","type":"print"}],"subject":[],"published":{"date-parts":[[1984,3,1]]}}}